Zura Bio Limited ZURA

Updated: 10 Aug 2026

NASDAQ | Biotech | Immunology and autoimmune diseases

No signal published yet

We already track Zura Bio and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Zura Bio free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Immunology and autoimmune diseases
We're already tracking Zura Bio Limited — here are the latest events we've registered

Recent News

  • On June 29, 2026, Zura Bio announced that it exceeded enrollment targets in its Phase 2 TibuSHIELD and TibuSURE trials evaluating tibulizumab. Topline data from the TibuSHIELD study in hidradenitis suppurativa is expected in the fourth quarter of 2026. The company also announced plans to initiate a Phase 2 trial for a third immune-mediated indication by year-end 2026.

What Firelda Watch includes for Zura Bio Limited

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Zura Bio Limited will be delivered in the same format.

Want to follow Zura Bio Limited? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Zura Bio free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Zura Bio Limited ZURA
Zura Bio — follow and we'll monitor it
Follow Zura Bio free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.